Memorial Sloan Kettering Cancer Center

Memorial Sloan Kettering Cancer Center, commonly known as MSK, is the world's oldest and largest private cancer center, located in New York City. Founded in 1884 as the New York Cancer Hospital, MSK has been exclusively dedicated to the prevention, diagnosis, and treatment of cancer for nearly 140 years. Ranked as the number one oncology hospital worldwide by Newsweek and consistently at the top of U.S. News & World Report's cancer hospital rankings, MSK is the definitive global destination for patients seeking the most advanced cancer care available. MSK operates with approximately 500 beds and employs more than 1,200 physicians and scientists who specialize in every aspect of cancer care. The institution treats approximately 400 distinct cancer subtypes, from the most common malignancies to the rarest and most complex cancers. This extraordinary breadth of expertise means that MSK physicians encounter and treat more cases of each cancer type than virtually any other institution, resulting in unparalleled experience and clinical outcomes. The hospital's 28 state-of-the-art operating rooms and advanced interventional suites enable the most complex surgical oncology procedures. Research is the cornerstone of MSK's mission, with approximately 1,000 clinical trials running at any given time. MSK researchers have contributed to 11 FDA-approved drugs developed through MSK-led clinical trials, fundamentally changing the standard of care for multiple cancer types. The Sloan Kettering Institute, the research arm of MSK, houses more than 120 laboratory research programs exploring cancer biology, immunology, genetics, and computational oncology. These discoveries drive the rapid translation of laboratory findings into clinical treatments, giving MSK patients access to therapies that are often years ahead of general availability. The David H. Koch Center for Cancer Care, a state-of-the-art outpatient facility, provides comprehensive cancer services across 23 floors, including consultation, chemotherapy infusion, radiation therapy, and surgical procedures. MSK's Proton Therapy Center is one of only a handful of hospital-based proton therapy facilities in the world, offering highly targeted radiation treatment that minimizes damage to surrounding healthy tissue, particularly beneficial for pediatric cancers, brain tumors, and cancers near critical structures. MSK is at the forefront of immunotherapy and cellular therapy, including CAR T-cell therapy, checkpoint inhibitor combinations, and cancer vaccine development. The institution's genomic sequencing program, MSK-IMPACT, analyzes tumor DNA from every patient to identify actionable mutations and match patients with targeted therapies or clinical trials. This precision medicine approach has become a model for cancer centers worldwide. The Griffin Pavilion expansion is adding 208 beds to the inpatient facility, significantly expanding MSK's capacity to serve more patients. For international patients, MSK's International Center provides dedicated concierge services including physician referrals, appointment coordination, medical record translation, interpreter services in multiple languages, visa assistance, travel and accommodation planning, and financial counseling. The center's team of international patient representatives ensures that patients from around the world receive seamless, culturally sensitive care throughout their treatment journey at MSK. Memorial Sloan Kettering Cancer Center's singular focus on cancer, combined with its world-leading research programs, unmatched clinical expertise, advanced treatment technologies, and comprehensive international patient services, makes it the ultimate destination for cancer patients seeking the best possible outcomes and the most innovative treatments available anywhere in the world.